Simon B. Zeichner, D.O.

Dr. Simon Zeichner is a double board-certified oncologist who is fellowship trained in hematology and medical oncology. He specializes in providing the best care to patients with all types of cancers at Baptist Medical Group – Oncology. He and his dedicated staff offer compassionate and dedicated health care and currently welcome new patients.

Medical Degree
Nova Southeastern College of Osteopathic Medicine
Fort Lauderdale, FL

Mount Sinai Medical Center of Florida
Miami, FL

Winship Cancer Institute of Emory University
Atlanta, GA

Board Certifications
American Board of Osteopathic Internal Medicine
American Board of Osteopathic Internal Medicine, Oncology/Hematology

American Society of Hematology
American Society of Clinical Oncology
American Medical Association
American College of Osteopathic Internists

Meet the Doctor

What about your line of work do you find most rewarding and why?
The most rewarding aspect of my job is helping people during one of the most vulnerable times in their lives and having the distinct opportunity to guide them through this period of time.
What is something about you that only your patients would know?
I am a fierce advocate for my patients and emphasize a comprehensive approach to their treatment.

How would a patient describe you?
A patient would describe me as very approachable, knowledgeable and up-to-date on the latest treatment breakthroughs. Interpersonally, they would describe me as someone who is caring, a good listener, comprehensive, passionate about his field, honest, and very accessible.

What’s your proudest moment as a doctor?
The proudest moments I have had as a physician have been when patients have told me that I was the first one to give them answers to a medical condition that was afflicting them, saved their life, gave them hope for the future, allowed them the chance to spend more time with their family, or gave them comfort while coping with a serious disease.

In your opinion, what’s the most important factor in a doctor-patient relationship?
I am a huge proponent for patient-physician rapport, as I believe in order for there to be a successful treatment environment, it is critical that there is trust and mutual respect between the patient and physician.

What can a patient expect when they have you as a doctor?
Patients that have me as their physician can expect a personable, dedicated, and hard-working doctor that will do everything he can to make the tough diagnosis, explain a complex medical disease or treatment, or address an unexpected side effect. Patients can expect someone who is very thoughtful and who takes a person-centered approach to develop individually tailored treatment plans.


1) Kohn CG, Zeichner SB, Chen Q, et al. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017;35(11):1194-1202. 

2) Zeichner SB, Zeichner RL, Gogineni K, et. Al. Cognitive Behavioral Therapy for Insomnia, Mindfulness, and Yoga in Patients With Breast Cancer with Sleep Disturbance: A Literature Review. Breast Cancer Basic Clin Res. 2017;11:117822341774556. 
3) Weeda ER, Caranfa JT, Zeichner SB, et al. External Validation of Generic and Cancer-Specific Risk Stratification Tools in Patients With Pulmonary Embolism and Active Cancer. J Natl Compr Cancer Netw. 2017;15(12):1476-1482. 
4) Kohn CG, Zeichner SB, Chen Q, et al. Reply to Á. Benedict et al. J Clin Oncol. 2017 Sep 10;35(26):3086-3087.
5) Zeichner SB, Goldstein DA, Kohn C, et al. Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. J Gastrointest Oncol. 2017 Jun;8(3):513-523. 
6) Zeichner SB, Stanislaw C, Meisel JL. Prevention and Screening in Hereditary Breast and Ovarian Cancer. Oncology (Williston Park). 2016;30(10). 
7) Zeichner SB, Kohn CG, Goldstein DA. Economics of ramucirumab for metastatic colorectal cancer. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):733-745. 
8) Zeichner SB, Zeichner RL, Gogineni K, Shatil S, Ioachimescu O. Cognitive Behavioral Therapy for Insomnia, Mindfulness, and Yoga in Patients With Breast Cancer with Sleep Disturbance: A Literature Review. Breast Cancer Basic Clin Res. 2017;11:1178223417745564. 
9) Zeichner SB, Terawaki H, & Gogineni K. (2016). A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer: Basic and Clinical Research. 10, 25–36. 
10) Diaby V, Adunlin G, Ali AA, Zeichner SB, Lopes G, Kohn C, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016; 160(1):187-196. 
11) Hamilton BK, Rybicki L, Abounader D, Adekola K, Advani A, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers CR, Ganguly S, Jagasia M, Kennedy VE, Kim DD, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner SB, Perales MA, Majhail NS. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute
Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2017 Jul;23(7):1117-1121
12) Zeichner SB, Gleason S, Antun A, Khoury HJ, Langston A, Heffner LT, Kota V, Gaddh M, Arellano M. Survival of patients diagnosed with primary refractory and relapsed acute myeloid leukemia from 2008-2012: A single institution experience. Clinical Lymphoma, Myeloma, & Leukemia. In press.
13) Kohn CG, Zeichner SB, Chen Q, et al. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017;35(11):1194-1202. 
14) Zeichner SB, Herna S, Mani A, et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat. 2015;153(3):617-624. 
15) Goldstein DA, Zeichner SB, McKibbin T. Management of advanced/metastatic melanoma: New and emerging treatment pathways, therapies, and challenges. Am J Manag Care. 2015 Sept 21; (10 Suppl): s234-41.
16) Goldstein DA, Zeichner SB, Bartnik CM, et al. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer. 2016;15(1):1-6. 
17) Zeichner SB, Arellano M. Secondary adult acute myeloid leukemia: A review of our evolving understanding of a complex disease process. Curr Treat Options Oncol. 2015 Aug; 16(8):355. 
18) Zeichner SB, Montero AJ (2016). Detecting cancer: Pearls for the primary care physician. Cleveland Clinic Journal of Medicine, 83(7), 515–23. 
19) Zeichner SB, Ambros T, Zaravinos J, et al. Defining the survival benchmark for breast cancer patients with systemic relapse. Breast Cancer (Auckl). 2015 Apr 15; 9:9-17.
20) Zeichner SB, Koru-Sengul T, Shah N, et al.Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer. Clin Breast Cancer. 2015 Feb 15;(1): e1-11. 
21) Diaby V, Adunlin G, Zeichner SB, et al. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014;147(2):433-441. 
22) Ambros T, Zeichner SB, Zaravinos J, et al. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat. 2014 Jul 14; 6(1):7-14. 
23) Zeichner SB, Cavalcante M, Barkin J. SUPPLEMENT USE AND GASTROINTESTINAL BLEEDING. Asian J Pharm Clin Res. 2014;7(7):194-201. Indexed on Google Scholar only.
24) Zeichner SB, Cavalcante L, Suciu GP, et al. Long-term survival of women with locally advanced breast cancer with ≥ 10 involved lymph nodes at diagnosis. Asian Pac J Cancer Prev. 2014;15(8):3435-3441. 
25) Zeichner SB, Alghamdi S, Elhammady G, Poppiti RJ, Castellano A. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia. Asian Pac J Cancer Prev. 2014; 15(4):1603-1609.
26) Alghamdi S, Gonzalez B, Howard L, Zeichner S, LaPietra A, Rosen G, Garcia G, Lamelas J, Goldszer R. Reducing Blood Utilization by Implementation of a Type-and-Screen Transfusion Policy A Single-Institution Experience. Am J Clin Pathol. 2014;141(6):892-895. Indexed as Zeichner S, as opposed to Zeichner SB.
27) Zeichner SB, Ruiz AL, Markward NJ, et al. Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev. 2014; 15(3):1155-62.
28) Zeichner SB, Harris A, Turner G, et al. An acquired factor VIII (FVIII) inhibitor in a patient with HIV and HCV: A case presentation and literature review. Case Rep Hematol. 2013; 2013:628513.
29) Zeichner SB, Cepeda J, Shukla R, et al. Pyogenic vertebral osteomyelitis with associated psoas abscess and pyomyositis. J Am Osteopath Assoc. 2013 Oct; 113(10):796. 
30) Frances N, Zeichner SB, Francavilla M, et al. Gastric small-cell carcinoma found on esophagogastroduodenoscopy: a case report and literature review. Case Rep Oncol Med. 2013;2013:475961. 
31) Zeichner RL, Kibler JL, Zeichner SB. Relationship Between Mindfulness-Based Stress Reduction and Immune Function in Cancer and HIV/AIDS. Cancer Clin Oncol. 2013;2(1):62. doi:10.5539/cco.v2n1p62. Indexed on Google Scholar only. 
32) Zeichner SB. Holding rhetoric to a new standard: What's the p value of that statement, senator? J Am Osteopath Assoc. October 2012; 112:648-649.
33) Zeichner SB, Ruiz A, Suciu G, et al. Trends in Kaposi’s sarcoma in Miami Beach from 1987-2007. ISRN Oncology. Vol. 2012, Article ID 642106, 10 pages, 2012. 
34) Zeichner SB. Need to oppose proposed ACGME common program requirements. J Am Osteopath Assoc. September 2012; 112:586-587.
35) Zeichner SB, Raj N, Francavilla M, et al. A de novo germline APC mutation (3927del5) in a patient with familial adenomatous polyposis: Case report and literature review. Clin Med Insights Oncol. 2012; 6 315-323. 
36) Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. J Can Res Ther 2012; 8:176-83. Indexed as Zeichner S, as opposed to Zeichner SB.
37) Zeichner SB. The failed Theratope vaccine: Ten years later. J Am Osteopath Assoc. August 2012; 112(8):482-483.
38) Zeichner, SB. The plight of my childhood community. J Am Osteopath Assoc. August 2012; 112(8):566.
39) Zeichner SB. Acute myeloid leukemia, genetics, and risk stratification: Data overload or ready for a breakthrough? J Am Osteopath Assoc. July 2012; 112:463-465.
40) Zeichner S, Cusnir M, Francavilla M. Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer: A Case Presentation. Cancer Clin Oncol. 2012;1(1):118. doi:10.5539/cco.v1n1p118. Indexed on Google Scholar only. 
41) Zeichner SB. Taking on the challenge: my experience with cancer research. American College of Osteopathic Internists Resident Newsletter. March/April 2012 Can be found on organization webpage only. 
42) Zeichner SB, Rodriguez E. Support legislation to address shortage of chemotherapy drugs [letter]. J Am Osteopath Assoc. 2012; 112(3):112.
43) Zeichner SB, Cusnir M, Francavilla M, Hirzel A. Typical bronchial carcinoid metastasizing to the brain: a case presentation. Case Rep Oncol. 2011 Sep 4; (3):602-10.